Targeted therapies: optimal first-line therapy for NSCLC with EGFR mutations. Nature reviews. Clinical oncology Neal, J. W., Sequist, L. V. 2010; 7 (2): 71-72

View details for DOI 10.1038/nrclinonc.2009.191

View details for PubMedID 20118973